Shedding light on prostate cancer

Nurse Practitioner

Volumn 34, Issue 10, 2009, Pages 24-33

  Wallace, Meredith ^a   Bailey, Donald E ^b   Brion, John ^b  

^a YALE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971532146     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000361301.26520.72     Document Type: Article

References (62)

1. American Cancer Society. Cancer Facts and Figures 2008
2. American Cancer Society. Cancer Facts & Figures 2005.
3. Centers for Disease Control. Prostate disease.
4. Wilt TJ, Partin MR. Prostate cancer intervention. Involving the patient in early detection and treatment. Postgrad Med. 2003;114(4):43-49.
5. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37(Suppl 8):S4-66.
6. Klotz LH. Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol. 2005;12(Suppl 2):21-24.
7. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(Suppl 10):2371-2490.
8. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc. 2005;80(7):899-907.
9. Delongchamps NB, Singh A, Haas GP. Epidemiology of prostate cancer in Africa: another step in the understanding of the disease? Curr Probl Cancer. 2007;31(3):226-236.
10. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate. 2008;68 (14):1582-1591.
11. Amin M, Jeyaganth S, Fahmy N, et al. Dietary habits and prostate cancer detection: a case-control study. Can Urol Assoc J. 2008;2(5):510-515.
12. Itsiopoulos C, Hodge A, Kaimakamis M. Can the Mediterranean diet prevent prostate cancer? Mol Nutr Food Res. 2009;53(2):227-239.
13. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, D.C.: AICR; 2007.
14. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52(2):331-343.
15. Freedland SJ, Wen J, Wuerstle M, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008;72(5):1102-1105.
16. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertson PC, Blot WJ, et al. American Society of Clinical Oncology Health Services Committee. American Urological Association Practice Guidelines Committee. Use of 5-Alpha reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guidelines. J Clin Oncol. 2009 Mar 20; 27(9): 1502-16.
17. National Cancer Institute. Prostate cancer treatment.
18. Gray M, Sims T. Prostate cancer: prevention and management of localized disease. Nurs Pract. 2006; 31(9):14-17, 21-22, 24-27, passim.
19. American Urological Association. Prostate specific antigen best practice statement.
20. Wallner LP, Sarma AV, Lieber MM, et al. Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the Olmsted County study. Cancer Epidemiol Biomarkers Prev. 2008;17 (12):3588-3592.
21. American Cancer Society. All about prostate cancer.
22. Lucia MS, Epstein JI, GoodmanPJ, et al. Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst. 2007;99: 1375-1383.
23. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:004720.
24. Lim LS, Sherin K, ACPM prevention practice committee. Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice. Am J Prev Med. 2008;34(2): 164-170.
25. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(3):192-199.
26. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-191.
27. American Joint Committee on Cancer. What is cancer staging?
28. Kramer KM, Bennett CL, Pickard AS, et al. Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer. 2005;4(1):15-23.
29. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23(32):8146-8151.
30. Gofrit ON, Shalhav AL. Radical prostatectomy: 100 years of evolution. Harefuah. 2008;147(7):639-642.
31. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165(2): 430-435.
32. Soleimani M, Hosseini SY, Aliasgari M, Dadkhah F, Lashay A, Amini E. Erectile dysfunction after prostatectomy: an evaluation of the risk factors. Scand J Urol Nephrol. 2009;1-5.
33. Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 1997;89 (15):1117-1123.
34. Miles CL, Candy B, Jones L, Williams R, Tookman A, King M. Interventions for sexual dysfunction following treatments for cancer. Cochrane Database Syst Rev. 2007(4):005540.
35. Smither AR, Guralnick ML, Davis NB, See WA. Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. BMC Urol. 2007;7(2):2-9.
36. Nahon I, Dorey D, Waddington G, Adams R. Systematic review of the treatment of post-prostatectomy incontinence. Urol Nurs. 2006;26(6):461-475, 482.
37. Ko WF, Sawatzky JA. Understanding urinary incontinence after radical prostatectomy: a nursing framework. Clin J Oncol Nurs. 2008;12(4):647-654.
38. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med. 2006;355(15):1583-1591.
39. Strief DM. An overview of prostate cancer: diagnosis and treatment. Urol Nurs. 2007;27(6):475-479.
40. Bott SR, Birtle AJ, Taylor CJ, Kirby RS. Prostate cancer management: an update on localized disease. Postgrad Med J. 2003;79(936):575-580.
41. Yoshioka Y. Current status and perspectives of brachytherapy for prostate cancer. Int J Clin Oncol. 2009;14:31-36.
42. Yoshioka Y, Nose T, Yoshida K, et al. High dose rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int. J. Radiat Oncol Biol Phys. 2003; 56(1):213-220.
43. Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46(1):77-81.
44. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24(33):5298-5304.
45. Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol. 2006;16(3):152-156.
46. Bailey DE, Jr, Wallace M, Mishel MH. Watching, waiting and uncertainty in prostate cancer. J Clin Nurs. 2007;16(4):734-741.
47. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8): 1650-1659.
48. Wallace M, Storms S. The needs of men with prostate cancer: results of a focus group study. Appl Nurs Res. 2007;20(4):181-187.
49. Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler J. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs. 2004;27(5):339-346.
50. Wallace M, Bailey DE, Whittemore R. Out of the black box: Expansion of a theory-based intervention to self-manage the uncertainty associated with active surveillance [AS] for prostate cancer. Research and Theory for Nursing Practice. In Press
51. National Comprehensive Cancer Network. Prostate cancer.
52. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the androgen deprivation syndrome in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166(4):465-471.
53. Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006(4):006019.
54. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-181.
55. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol. 2001;166(2):508-515.
56. Wirth MP, Hakenberg OW, Froehner M. Antiandrogens in the treatment of prostate cancer. Eur Urol. 2007;51(2):306-313.
57. Harrington JM, Jones EG, Badger T. Body image perceptions in men with prostate cancer. Oncol Nurs Forum. 2009;36(2):167-172.
58. Nobes JP, Langley SE, Laing RW. Metabolic syndrome and prostate cancer: a review. Clin Oncol (R Coll Radiol). 2009;21(3):183-191.
59. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 2009;12:13-16.
60. Lindqvist O, Rasmussen BH, Widmark A. Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases. Eur J Oncol Nurs. 2008;1:283-290.
61. Lattouf JB, Saad F. Preservation of bone health in prostate cancer. Curr Opin Support Palliat Care. 2007;1(3):192-197.
62. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum. 2003;30(2):303-309.